Tielong Liu

Tielong Liu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2023 in Advanced Science
Verified
Journal Article
Open access
YHYi‐Wei Hu
Yi‐Wei Hu
YWYuheng Wang
Yuheng Wang
FYFang Yang
Fang Yang
Dingxin LiuDingxin Liu
Dingxin Liu
GLGuang‐Hao Lu
Guang‐Hao Lu
YZYABIN ZHU
YABIN ZHU
Electrical stimulation (ES) is proposed as a therapeutic solution for managing chronic wounds. However, its widespread clinical adoption is limited by the requirement of additional extracorporeal devices to power ES‐based wound dressings. In this study, a novel sandwich‐structured photovoltaic microcurrent hydrogel dressing (PMH dressing) is designed for treating diabetic wounds. This innovative dressing comprises flexible organic photovoltaic (OPV) cells, a flexible micro–electro–mechanical systems (MEMS) electrode, and a multifunctional hydrogel serving as an electrode–tissue interface. The PMH dressing is engineered to administer ES, mimicking the physiological injury current occurring naturally in wounds when exposed to light; thus, facilitating wound healing. In vitro experiments are performed to validate the PMH dressing's exceptional biocompatibility and robust antibacterial properties. In vivo experiments and proteomic analysis reveal that the proposed PMH dressing significantly accelerates the healing of infected diabetic wounds by enhancing extracellular matrix regeneration, eliminating bacteria, regulating inflammatory responses, and modulating vascular functions. Therefore, the PMH dressing is a potent, versatile, and effective solution for diabetic wound care, paving the way for advancements in wireless ES wound dressings.

1 April 2019 in World Neurosurgery
Verified
Journal Article
Closed access
BXBaoquan Xin
Baoquan Xin
GCGuanghui Chen
Guanghui Chen
YWYang Wang
Yang Wang
GBGuangjian Bai
Guangjian Bai
XGXin Gao
Xin Gao
TLTielong Liu
Tielong Liu

1 November 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
SCShuang Cao
Shuang Cao
LLLin Li
Lin Li
YDYan Du
Yan Du
JGJufen Gan
Jufen Gan
JWJing Wang
Jing Wang
TLTielong Liu
Tielong Liu

19 October 2021 in European Spine Journal
Verified
Journal Article
Closed access
PDF file
SCShuang Cao
Shuang Cao
XGXin Gao
Xin Gao
YZYue Zhang
Yue Zhang
YWYifan Wang
Yifan Wang
JWJing Wang
Jing Wang
TLTielong Liu
Tielong Liu

26 March 2024 in Chinese Journal of Traumatology
Verified
Journal Article
Open access
LCLin-Fei Cheng
Lin-Fei Cheng
CYChao-Qun You
Chao-Qun You
CPCheng Peng
Cheng Peng
JRJia-Ji Ren
Jia-Ji Ren
KGKai Guo
Kai Guo
TLTielong Liu
Tielong Liu
Spinal cord injury (SCI) is a devastating traumatic disease seriously impairing the quality of life in patients. Expectations to allow the hopeless central nervous system to repair itself after injury are unfeasible. Developing new approaches to regenerate the central nervous system is still the priority. Exosomes derived from mesenchymal stem cells (MSC-Exo) have been proven to robustly quench the inflammatory response or oxidative stress and curb neuronal apoptosis and autophagy following SCI, which are the key processes to rescue damaged spinal cord neurons and restore their functions. Nonetheless, MSC-Exo in SCI received scant attention. In this review, we reviewed our previous work and other studies to summarize the roles of MSC-Exo in SCI and its underlying mechanisms. Furthermore, we also focus on the application of exosomes as drug carriers in SCI. In particular, it combs the advantages of exosomes as drug carriers for SCI, imaging advantages, drug types, loading methods, etc., which provides the latest progress for exosomes in the treatment of SCI, especially drug carriers.

2 February 2021 in Global Spine Journal
Verified
Journal Article
Open access
PDF file
XGXin Gao
Xin Gao
ZWZheyu Wu
Zheyu Wu
TWTao Wang
Tao Wang
JCJiashi Cao
Jiashi Cao
GBGuangjian Bai
Guangjian Bai
JXJianru Xiao
Jianru Xiao
Study Design: Retrospective study. Objectives: Although the role of surgery in the management of metastatic spinal cord compression (MSCC) has been well established, elderly patients may still be denied surgery because of higher risk of complications and shorter life expectancy. The purpose of this study was to determine whether elderly patients with MSCC could benefit from surgery and discuss the criteria for surgical decision-making in such patients. Methods: Enrolled in this study were 55 consecutive patients aged 75 years or older who were surgically treated for MSCC in our center. Prognostic factors predicting overall survival (OS) were explored by the Kaplan-Meier method and Cox regression model. The quality of life (QoL) of the patients was evaluated by the SOSGOQ and compared using Student’s t test. Risk factors for postoperative complications were identified by Chi-square test and multiple logistic regression analysis. Results: Surgical treatment for MSCC substantially improved the neurological function in 55.8% patients and QoL in 88.5% patients with acceptable rates of postoperative complications (16.4%), reoperation (9.1%), and 30-day mortality (1.8%). Postoperative ECOG-PS of 1-2, total en-bloc spondylectomy (TES), and postoperative chemotherapy were favorable prognostic factors for OS, while a high Charlson Comorbidity Index (CCI) and a long operation time were risk factors for postoperative complications. Conclusions: Surgery should be encouraged for elderly patients with MSCC 1) who are compromised by the current or potential neurological dysfunction; 2) with radioresistant tumors; 3) with spinal instability; and 4) with no comorbidity, ECOG-PS of 0-2, and systemic treatment adherence. In addition, surgery should be performed by a skilled and experienced surgical team.